<DOC>
	<DOCNO>NCT01804218</DOCNO>
	<brief_summary>The purpose study test hypothesis 18—22 week treatment inverse agonist nadolol improve airway hyperresponsiveness patient mild asthma , compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Beta-adrenoceptor Inverse Agonist , Nadolol , Mild Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Nadolol</mesh_term>
	<criteria>Individuals meet follow criterion eligible enrollment study participant : 1 . Males female physiciandiagnosed asthma age 18 60 . 2 . Prebronchodilator FEV1 80 % great predict value 3 . Baseline PC20 ( base FEV1 ) ≤ 4 mg/ml methacholine challenge test . 4 . Asthma Control Questionnaire Score ( ACQ ) &lt; 1.25 5 . Baseline blood pressure ≥ 110/65mm Hg 6 . Baseline pulse rate ≥ 60 beats/min . 7 . Neversmoker formersmoker &lt; 10 pack.year smoke within 1 year . 8 . Able complete diary card comply study procedure . 9 . Females childbearing age may participate negative pregnancy test , nonlactating , agree practice adequate birth control method ( abstinence , combination barrier spermicide , hormonal ) duration study . Subjects meet ANY follow criterion eligible enrollment : 1 . Inability unwillingness participant give write informed consent 2 . History upper/lower respiratory tract infection asthma exacerbation require systemic steroid within 6 week Visit 1 3 . Use rescue medication ( e.g. , albuterol ) twice per week week precede Visit 1 exclude use medication preventative prior exercise . 4 . History hospitalization asthma precede year 5 . History intubation asthma 6 . Currently diagnose chronic obstructive pulmonary disease ( COPD ) 7 . Currently take betablocker medication 8 . History adverse reaction allergy betablocker medication 9 . History neurological , hepatic , renal , medical condition may interfere interpretation data patient 's participation study may increase safety concern 10 . Current diabetes hyperthyroidism 11 . History cardiovascular disease include uncontrolled hypertension ( BP &gt; 160/100 ) , ischemic heart disease , congestive heart failure , valvular heart disease cardiomyopathy 12 . Known allergy sensitivity atropine ipratropium bromide 13 . Abnormal entry laboratory value baseline except follow test , value outside normal limit acceptable follow : Hct ≥ 30 % , platelet count &gt; 100,000 , ALT AST &lt; 1.5 x upper normal limit 14 . Known bleed disorder , platelet count &lt; 100,000 , PT PTT &gt; 1.5 x normal control ( participate bronchoscopy substudy ) 15 . Known allergy lidocaine ( participate bronchoscopy substudy ) 16 . Documented selfreported current history alcoholism drug abuse 17 . Participation another research trial within 30 day start trial 18 . Unwillingness inability comply study procedures 19 . Inability swallow study medication capsule 20 . Use exclusion medication within time period specify 21 . Pregnant nursing 22 . Receiving allergen immunotherapy ( desensitization injection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>